1,29 €
1,26 % heute
L&S, 2. Mai, 20:45 Uhr
ISIN
US30068X1037
Symbol
XGN
Berichte

Exagen Inc Aktie News

Neutral
GlobeNewsWire
2 Tage alt
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's re...
Neutral
GlobeNewsWire
6 Tage alt
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
Neutral
Seeking Alpha
etwa 2 Monate alt
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
etwa 2 Monate alt
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Neutral
GlobeNewsWire
etwa 2 Monate alt
CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, w...
Neutral
GlobeNewsWire
etwa 2 Monate alt
CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review th...
Neutral
GlobeNewsWire
4 Monate alt
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
Neutral
Seeking Alpha
5 Monate alt
Exagen Inc. (NASDAQ:XGN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conf...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen